B3P Stock Overview
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
BioPharma Credit PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$0.96 |
| 52 Week Low | US$0.81 |
| Beta | 0.22 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 5.32% |
| 5 Year Change | 4.63% |
| Change since IPO | 1.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| B3P | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -2.0% |
| 1Y | n/a | 17.8% | -0.3% |
Return vs Industry: Insufficient data to determine how B3P performed against the German Capital Markets industry.
Return vs Market: Insufficient data to determine how B3P performed against the German Market.
Price Volatility
| B3P volatility | |
|---|---|
| B3P Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B3P has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine B3P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.bpcruk.com |
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.
BioPharma Credit PLC Fundamentals Summary
| B3P fundamental statistics | |
|---|---|
| Market cap | €1.26b |
| Earnings (TTM) | €83.86m |
| Revenue (TTM) | €102.54m |
15.0x
P/E Ratio12.3x
P/S RatioIs B3P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B3P income statement (TTM) | |
|---|---|
| Revenue | US$103.88m |
| Cost of Revenue | US$0 |
| Gross Profit | US$103.88m |
| Other Expenses | US$18.92m |
| Earnings | US$84.96m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 14, 2022
| Earnings per share (EPS) | 0.062 |
| Gross Margin | 100.00% |
| Net Profit Margin | 81.79% |
| Debt/Equity Ratio | 0.0% |
How did B3P perform over the long term?
See historical performance and comparison